Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OpCT-001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : BlueRock Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
BlueRock Exercise Option to License FUJIFILM's OpCT-001 for Primary Photoreceptor Disease
Details : Under the agreement, BlueRock exercised its option to exclusively license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for primary photoreceptor diseases.
Brand Name : OpCT-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 23, 2024
Lead Product(s) : OpCT-001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : BlueRock Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : iPSC-derived Cell Therpay
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Century Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 09, 2023
Lead Product(s) : iPSC-derived Cell Therpay
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Century Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?